SOUTH Australia's Flinders Centre for Innovation in Cancer has been awarded a major $553,196 grant to improve the survival and recovery of colorectal cancer patients via a simple blood test.
The Australian-developed "Colvera" test, which targets tumour DNA, promises early notification of risk of recurrence, researchers say, with a significant proportion of patients seeing their bowel cancer return within three years despite having surgery.
Chief investigator Dr Erin Symonds said the test could allow specialists to focus chemotherapy, on patients who are most likely to benefit, while avoiding it in those who do not need it.
The Colvera test was developed in partnership with cancer diagnostics company Clinical Genomics, and is currently being used for research purposes in Australia.
More info at news.flinders.edu.au.
The above article was sent to subscribers in Pharmacy Daily's issue from 07 Jan 19
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 07 Jan 19